KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2020 - 2025)

Esperion Therapeutics' Amortization of Deferred Charges history spans 6 years, with the latest figure at -$9.8 million for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 5801.16% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached $9.1 million, up 502.58%, while the annual FY2025 figure was $9.1 million, 507.01% up from the prior year.
  • Amortization of Deferred Charges reached -$9.8 million in Q4 2025 per ESPR's latest filing, down from $9.1 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $9.1 million in Q2 2025 to a low of -$9.8 million in Q4 2025.
  • Average Amortization of Deferred Charges over 5 years is $692200.0, with a median of $408500.0 recorded in 2021.
  • The largest YoY upside for Amortization of Deferred Charges was 2175.0% in 2025 against a maximum downside of 5801.16% in 2025.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $407000.0 in 2021, then grew by 1.72% to $414000.0 in 2022, then crashed by 405.8% to -$1.3 million in 2023, then soared by 113.59% to $172000.0 in 2024, then crashed by 5801.16% to -$9.8 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Amortization of Deferred Charges are -$9.8 million (Q4 2025), $9.1 million (Q3 2025), and $9.1 million (Q2 2025).